April 2, 2018 / 12:43 PM / 3 months ago

BRIEF-Rhythm Pharma Announces Licensing Agreement With Takeda

April 2 (Reuters) - Rhythm Pharmaceuticals Inc:

* RHYTHM PHARMACEUTICALS ANNOUNCES LICENSING AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF PRECLINICAL TREATMENT FOR PRADER-WILLI SYNDROME

* RHYTHM PHARMACEUTICALS INC - ‍RHYTHM EXPECTS TO FILE INVESTIGATIONAL NEW DRUG APPLICATION IN Q1 OF 2020​

* RHYTHM PHARMACEUTICALS INC - ‍ ACQUIRED EXCLUSIVE, WORLDWIDE RIGHTS FROM TAKEDA TO DEVELOP AND COMMERCIALIZE T-3525770 (NOW RM-853)​

* RHYTHM PHARMACEUTICALS INC - ‍UNDER TERMS, CO WILL ASSUME SOLE RESPONSIBILITY FOR GLOBAL PRODUCT DEVELOPMENT AND COMMERCIALIZATION OF RM-853​

* RHYTHM PHARMACEUTICALS-‍ TAKEDA TO GET UPFRONT PAYMENT OF $5 MLN IN CO'S STOCK, BACK-END DEVELOPMENT MILESTONES, SINGLE-DIGIT ROYALTIES ON RM-853 SALES​

* RHYTHM PHARMACEUTICALS INC - ‍WILL EXPLORE OPPORTUNITIES TO EVALUATE SETMELANOTIDE AND RM-853 IN COMBINATION, AS THERE MAY BE COMPLEMENTARY EFFECTS​​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below